Cancer Immunology, Immunotherapy

, Volume 59, Issue 10, pp 1531–1541 | Cite as

A polysaccharide extracted from Grifola frondosa enhances the anti-tumor activity of bone marrow-derived dendritic cell-based immunotherapy against murine colon cancer

  • Yuki Masuda
  • Koichi Ito
  • Morichika Konishi
  • Hiroaki Nanba
Original Article

Abstract

We previously isolated the novel heteropolysaccharide maitake Z-fraction (MZF) from the maitake mushroom (Grifola frondosa), and demonstrated that MZF significantly inhibited tumor growth by inducing cell-mediated immunity. In this study, we demonstrated that MZF upregulated the expression of CD80, CD86, CD83, and MHC II on bone marrow-derived dendritic cells (DCs) and significantly increased interleukin-12 (IL-12) and tumor necrosis factor-alpha production by DCs in a dose-dependent manner. MZF-treated DCs significantly stimulated both allogeneic and antigen-specific syngenic T cell responses and enhanced antigen-specific interferon-gamma (IFN-γ) production by syngenic CD4+ T cells; however, MZF-treated DCs did not affect IL-4 production. Furthermore, the enhancement of IFN-γ production in CD4+ T cells, which was induced by MZF-treated DCs, was completely inhibited by the addition of an anti-IL-12 antibody. These results indicate that MZF induced DC maturation and antigen-specific Th1 response by enhancing DC-produced IL-12. We also demonstrated that DCs pulsed with colon-26 tumor lysate in the presence of MZF induced both therapeutic and preventive effects on colon-26 tumor development in BALB/c mice. These results suggest that MZF could be a potential effective adjuvant to enhance immunotherapy using DC-based vaccination.

Keywords

Dendritic cells Vaccines Grifola frondosa BRM IL-12 

References

  1. 1.
    Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252CrossRefPubMedGoogle Scholar
  2. 2.
    Nencioni A, Brossart P (2004) Cellular immunotherapy with dendritic cells in cancer: current status. Stem Cells 22:501–513CrossRefPubMedGoogle Scholar
  3. 3.
    Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, Schmid B, Schmitt E, Schild H, Radsak MP (2006) Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108:544–550CrossRefPubMedGoogle Scholar
  4. 4.
    Sugiyama T, Hoshino K, Saito M, Yano T, Sasaki I, Yamazaki C, Akira S, Kaisho T (2008) Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7. Int Immunol 20:1–9CrossRefPubMedGoogle Scholar
  5. 5.
    Reis e Sousa C (2006) Dendritic cells in a mature age. Nat Rev Immunol 6:476–483CrossRefPubMedGoogle Scholar
  6. 6.
    Curtsinger JM, Lins DC, Mescher MF (2003) Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 197:1141–1151CrossRefPubMedGoogle Scholar
  7. 7.
    Ballestrero A, Boy D, Moran E, Cirmena G, Brossart P, Nencioni A (2008) Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev 60:173–183CrossRefPubMedGoogle Scholar
  8. 8.
    Underhill DM (2007) Collaboration between the innate immune receptors dectin-1, TLRs, and Nods. Immunol Rev 219:75–87CrossRefPubMedGoogle Scholar
  9. 9.
    Yan J, Vetvicka V, Xia Y, Coxon A, Carroll MC, Mayadas TN, Ross GD (1999) Beta-glucan, a “specific” biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol 163:3045–3052PubMedGoogle Scholar
  10. 10.
    Brown GD (2006) Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol 6:33–43CrossRefPubMedGoogle Scholar
  11. 11.
    Goodridge HS, Wolf AJ, Underhill DM (2009) Beta-glucan recognition by the innate immune system. Immunol Rev 230:38–50CrossRefPubMedGoogle Scholar
  12. 12.
    Leibundgut-Landmann S, Osorio F, Brown GD, Reis e Sousa C (2008) Stimulation of dendritic cells via the dectin-1/Syk pathway allows priming of cytotoxic T-cell responses. Blood 112:4971–4980CrossRefPubMedGoogle Scholar
  13. 13.
    Sheng KC, Pouniotis DS, Wright MD, Tang CK, Lazoura E, Pietersz GA, Apostolopoulos V (2006) Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 118:372–383CrossRefPubMedGoogle Scholar
  14. 14.
    Ren Z, Guo Z, Meydani SN, Wu D (2008) White button mushroom enhances maturation of bone marrow-derived dendritic cells and their antigen presenting function in mice. J Nutr 138:544–550PubMedGoogle Scholar
  15. 15.
    Kim GY, Lee MY, Lee HJ, Moon DO, Lee CM, Jin CY, Choi YH, Jeong YK, Chung KT, Lee JY et al (2005) Effect of water-soluble proteoglycan isolated from Agaricus blazei on the maturation of murine bone marrow-derived dendritic cells. Int Immunopharmacol 5:1523–1532CrossRefPubMedGoogle Scholar
  16. 16.
    Park SK, Kim GY, Lim JY, Kwak JY, Bae YS, Lee JD, Oh YH, Ahn SC, Park YM (2003) Acidic polysaccharides isolated from Phellinus linteus induce phenotypic and functional maturation of murine dendritic cells. Biochem Biophys Res Commun 312:449–458CrossRefPubMedGoogle Scholar
  17. 17.
    Deng G, Lin H, Seidman A, Fornier M, D’Andrea G, Wesa K, Yeung S, Cunningham-Rundles S, Vickers AJ, Cassileth B (2009) A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. J Cancer Res Clin Oncol 135:1215–1221CrossRefPubMedGoogle Scholar
  18. 18.
    Nanba H, Hamaguchi A, Kuroda H (1987) The chemical structure of an antitumor polysaccharide in fruit bodies of Grifola frondosa (maitake). Chem Pharm Bull 35:1162–1168PubMedGoogle Scholar
  19. 19.
    Ito K, Masuda Y, Yamasaki Y, Yokota Y, Nanba H (2009) Maitake beta-glucan enhances granulopoiesis and mobilization of granulocytes by increasing G-CSF production and modulating CXCR4/SDF-1 expression. Int Immunopharmacol 9:1189–119615CrossRefPubMedGoogle Scholar
  20. 20.
    Masuda Y, Inoue M, Miyata A, Mizuno S, Nanba H (2009) Maitake beta-glucan enhances therapeutic effect and reduces myelosupression and nephrotoxicity of cisplatin in mice. Int Immunopharmacol 9:620–626CrossRefPubMedGoogle Scholar
  21. 21.
    Masuda Y, Matsumoto A, Toida T, Oikawa T, Ito K, Nanba H (2009) Characterization and antitumor effect of a novel polysaccharide from Grifola frondosa. J Agric Food Chem 57:10143–10149CrossRefPubMedGoogle Scholar
  22. 22.
    Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:1693–1702CrossRefPubMedGoogle Scholar
  23. 23.
    Kim E, Kim SH, Kim S, Cho D, Kim TS (2008) AIMP1/p43 protein induces the maturation of bone marrow-derived dendritic cells with T helper type 1-polarizing ability. J Immunol 180:2894–2902PubMedGoogle Scholar
  24. 24.
    DeKruyff RH, Fang Y, Wolf SF, Umetsu DT (1995) IL-12 inhibits IL-4 synthesis in keyhole limpet hemocyanin-primed CD4+ T cells through an effect on antigen-presenting cells. J Immunol 154:2578–2587PubMedGoogle Scholar
  25. 25.
    Lambert LA, Gibson GR, Maloney M, Durell B, Noelle RJ, Barth RJ Jr (2001) Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 61:641–646PubMedGoogle Scholar
  26. 26.
    Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML (1999) T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 20:561–567CrossRefPubMedGoogle Scholar
  27. 27.
    Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T, Flavell RA (2004) Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell 117:515–526CrossRefPubMedGoogle Scholar
  28. 28.
    Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P (2000) Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 164:4507–4512PubMedGoogle Scholar
  29. 29.
    Giermasz AS, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, Gooding W, Kalinski P (2009) Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother 58:1329–1336CrossRefPubMedGoogle Scholar
  30. 30.
    Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133–146CrossRefPubMedGoogle Scholar
  31. 31.
    Gao FG, Wan da F, Gu JR (2007) Ex vivo nicotine stimulation augments the efficacy of therapeutic bone marrow-derived dendritic cell vaccination. Clin Cancer Res 13:3706–3712CrossRefPubMedGoogle Scholar
  32. 32.
    Gonzalez-Carmona MA, Lukacs-Kornek V, Timmerman A, Shabani S, Kornek M, Vogt A, Yildiz Y, Sievers E, Schmidt-Wolf IG, Caselmann WH et al (2008) CD40 ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. Hepatology 48:157–168CrossRefPubMedGoogle Scholar
  33. 33.
    Rogers NC, Slack EC, Edwards AD, Nolte MA, Schulz O, Schweighoffer E, Williams DL, Gordon S, Tybulewicz VL, Brown GD, Reis e Sousa C (2005) Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity 22:507–517CrossRefPubMedGoogle Scholar
  34. 34.
    Herre J, Marshall AS, Caron E, Edwards AD, Williams DL, Schweighoffer E, Tybulewicz V, Reis e Sousa C, Gordon S, Brown GD (2004) Dectin-1 uses novel mechanisms for yeast phagocytosis in macrophages. Blood 104:4038–4045CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Yuki Masuda
    • 1
  • Koichi Ito
    • 2
  • Morichika Konishi
    • 1
  • Hiroaki Nanba
    • 1
  1. 1.Department of Microbial ChemistryKobe Pharmaceutical UniversityKobeJapan
  2. 2.Science 2 (G12), School of Medical ScienceGriffith UniversitySouthportAustralia

Personalised recommendations